Clinical Trials Logo

Leg Ulcers clinical trials

View clinical trials related to Leg Ulcers.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00762138 Terminated - Wounds Clinical Trials

The AutoloGelâ„¢ Post-Market Surveillance (TAPS) Program

TAPS
Start date: September 2008
Phase: N/A
Study type: Interventional

AutoloGelâ„¢ Post-Market Surveillance Program Purpose:Evaluate the incidence of hematologic and immunologic adverse events, including coagulopathies in patients with wounds to which AutoloGelâ„¢ was applied. Design:Prospective, open label, patient registry. Investigator Sites: 3 Enrollment Size: 300 Subject Population: Patients with exuding wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and for the management of mechanically or surgically-debrided wounds. Primary Objective Safety: Assess the incidence of hematologic (coagulopathies), immunologic (including anaphylaxis) and other adverse events associated with the application of AutoloGel on exuding wounds, such as leg ulcers, pressure ulcers and diabetic ulcers and during the management of mechanically or surgically-debrided wounds. Primary Safety Endpoint: Absence of coagulopathies caused by inhibitors to coagulation Factor V as determined by a significant prolongation of the prothrombin (PT) time and confirmed by severe depletion of Factor V activity with a positive Bethesda Assay for anti-Factor V functional inhibitors.